Clinical Trials
7
Active:0
Completed:4
Trial Phases
4 Phases
Early Phase 1:1
Phase 1:3
Phase 3:1
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (50.0%)Early Phase 1
1 (16.7%)Not Applicable
1 (16.7%)Phase 3
1 (16.7%)Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Zhuhai Beihai Biotech Co., Ltd
- Target Recruit Count
- 48
- Registration Number
- NCT06732531
An Relative Bioavailability Study of BH006 for Injection in Healthy Subjects
Early Phase 1
Not yet recruiting
- Conditions
- Bioavailability
- Interventions
- Drug: BH006 for injection
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Zhuhai Beihai Biotech Co., Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT06427681
A Study of BH009 in Head and Neck Squamous Cell Carcinoma and Ovarian Cancer
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Zhuhai Beihai Biotech Co., Ltd
- Target Recruit Count
- 24
- Registration Number
- NCT06232863
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
🇨🇳The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
Phase I Clinical Trial of BH002 in Patients With Advanced Solid Tumors
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Zhuhai Beihai Biotech Co., Ltd
- Target Recruit Count
- 12
- Registration Number
- NCT06231277
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Bioequivalence Study of Docetaxel Injection in Patients With Solid Tumours
Phase 3
Completed
- Conditions
- DocetaxelSolid TumoursBioequivalence
- Interventions
- Drug: BH009 (Docetaxel injection)
- First Posted Date
- 2021-05-17
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Zhuhai Beihai Biotech Co., Ltd
- Target Recruit Count
- 46
- Registration Number
- NCT04889599
- Locations
- 🇮🇳
HCG City Cancer center, Andra, India
🇮🇳Nirmal Hospital Pvt. Ltd, Gujrat, India
🇮🇳HCG Manavata Cancer Centre, Mahara, India
News
No news found